<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

CRC Sensitivity to Proteasome Inhibitor Investigated

Colorectal cancer (CRC) has a low 5 year survival rate, due to the late diagnosis of advanced disease and tumor relapse due to chemotherapeutic resistance. Therefore, early diagnosis, targeted screening, and development of new therapies are needed to improve the prognosis of CRC patients.